Hong Kong Pharma Digital Technology Holdings Ltd. held its annual meeting of stockholders on December 12, 2025. All proposals on the agenda were approved. The meeting approved the re-election of Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, and Dr. Kam Leung Chan as directors. Onestop Assurance PAC was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The authorized share capital was increased from US$100,000 to US$1,000,000, and ordinary shares were re-designated and re-classified into Class A and Class B ordinary shares. The implementation of a reverse share split and share consolidation was approved. The company's name will be changed to Cellyan Biotechnology Co., Ltd, and the foreign name will be changed to 生研生物公司. Adoption of the fourth amended and restated memorandum and articles of association was approved. The company will repurchase 7,150,000 Class A Ordinary Shares registered in the name of TUTU Business Services Limited and issue Class B Ordinary Shares. The Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan was also adopted.